PDF(Pubmed)
Abstract：
BACKGROUND: Olfactory dysfunction is a common manifestation in COVID-19 patients and can significantly impact their quality of life. Corticosteroids have been proposed as a potential treatment, but their efficacy remains controversial. This systematic review and meta-analysis aims to comprehensively analyze the efficacy of corticosteroid therapy for treating COVID-19-related olfactory dysfunction.
METHODS: A literature search was conducted in PubMed, Cochrane Library, and Embase databases up to March 1, 2023. Randomized controlled trials investigating the effects of corticosteroids on olfactory dysfunction in patients with COVID-19 were included. The primary outcome was the olfactory score at the end of follow-up, and the secondary outcomes were the duration and the rate of recovery from olfactory dysfunction.
RESULTS: Seven randomized controlled trials with 999 participants were included in the meta-analysis. Compared with the control group, corticosteroid treatment resulted in a statistically significant improvement in olfactory score with a standardized mean difference of 0.55 (95% CI: 0.15 to 0.95). Topical corticosteroids were found to be effective, but systemic corticosteroids were not. In addition, longer durations and higher dosages of corticosteroids treatment may also be associated with significant improvements in olfactory scores. No significant effect was observed on the duration or recovery rate of olfactory dysfunction.
CONCLUSIONS: Our findings suggest that topical corticosteroid treatment is a viable option for improving COVID-19-related olfactory dysfunction, but further research is needed to investigate optimal treatment protocols and safety profiles.
METHODS: A literature search was conducted in PubMed, Cochrane Library, and Embase databases up to March 1, 2023. Randomized controlled trials investigating the effects of corticosteroids on olfactory dysfunction in patients with COVID-19 were included. The primary outcome was the olfactory score at the end of follow-up, and the secondary outcomes were the duration and the rate of recovery from olfactory dysfunction.
RESULTS: Seven randomized controlled trials with 999 participants were included in the meta-analysis. Compared with the control group, corticosteroid treatment resulted in a statistically significant improvement in olfactory score with a standardized mean difference of 0.55 (95% CI: 0.15 to 0.95). Topical corticosteroids were found to be effective, but systemic corticosteroids were not. In addition, longer durations and higher dosages of corticosteroids treatment may also be associated with significant improvements in olfactory scores. No significant effect was observed on the duration or recovery rate of olfactory dysfunction.
CONCLUSIONS: Our findings suggest that topical corticosteroid treatment is a viable option for improving COVID-19-related olfactory dysfunction, but further research is needed to investigate optimal treatment protocols and safety profiles.
摘要：
背景：嗅觉功能障碍是COVID-19患者的常见表现，可显著影响其生活质量。皮质类固醇已被提议作为一种潜在的治疗方法，但它们的功效仍存在争议。本系统评价和荟萃分析旨在全面分析糖皮质激素治疗COVID-19相关嗅觉功能障碍的疗效。
方法：在PubMed，科克伦图书馆,和Embase数据库截至2023年3月1日。纳入了研究糖皮质激素对COVID-19患者嗅觉功能障碍影响的随机对照试验。主要结果是随访结束时的嗅觉评分，次要结局是嗅觉功能障碍的持续时间和恢复率.
结果：有999名参与者的7项随机对照试验被纳入荟萃分析。与对照组相比,皮质类固醇治疗可显著改善嗅觉评分,标准化平均差异为0.55(95%CI:0.15~0.95).外用皮质类固醇被发现是有效的，但全身性皮质类固醇没有。此外,更长的持续时间和更高的皮质类固醇治疗剂量也可能与嗅觉评分的显著改善相关.对嗅觉功能障碍的持续时间或恢复率无明显影响。
结论：我们的研究结果表明，局部皮质类固醇治疗是改善COVID-19相关嗅觉功能障碍的可行选择，但需要进一步的研究来研究最佳治疗方案和安全性.
方法：在PubMed，科克伦图书馆,和Embase数据库截至2023年3月1日。纳入了研究糖皮质激素对COVID-19患者嗅觉功能障碍影响的随机对照试验。主要结果是随访结束时的嗅觉评分，次要结局是嗅觉功能障碍的持续时间和恢复率.
结果：有999名参与者的7项随机对照试验被纳入荟萃分析。与对照组相比,皮质类固醇治疗可显著改善嗅觉评分,标准化平均差异为0.55(95%CI:0.15~0.95).外用皮质类固醇被发现是有效的，但全身性皮质类固醇没有。此外,更长的持续时间和更高的皮质类固醇治疗剂量也可能与嗅觉评分的显著改善相关.对嗅觉功能障碍的持续时间或恢复率无明显影响。
结论：我们的研究结果表明，局部皮质类固醇治疗是改善COVID-19相关嗅觉功能障碍的可行选择，但需要进一步的研究来研究最佳治疗方案和安全性.
